Response rate
. | Arm A; n = 200 . | Arm B; n = 196 . | Arm C; n = 201 . | P . |
|---|---|---|---|---|
| After VAD regimen, n (%) | NS | |||
| CR or VGPR | 30 (15) | 30 (15) | 32 (16) | |
| At randomization, n (%) | NS | |||
| CR or VGPR | 94 (47) | 92 (47) | 100 (50) | |
| PR | 84 (42) | 84 (43) | 78 (39) | |
| MR | 20 (10) | 16 (8) | 20 (10) | |
| PD | 2 (1) | 4 (2) | 3 (1) | |
| Best response after randomization, n (%) | .001 | |||
| CR or VGPR | 110 (55) | 112 (57) | 135 (67) | |
| PR | 74 (37) | 72 (37) | 60 (30) | |
| MR | 15 (7.5) | 11 (5.5) | 6 (3) | |
| PD | 1 (0.5) | 1 (0.5) | 0 |
. | Arm A; n = 200 . | Arm B; n = 196 . | Arm C; n = 201 . | P . |
|---|---|---|---|---|
| After VAD regimen, n (%) | NS | |||
| CR or VGPR | 30 (15) | 30 (15) | 32 (16) | |
| At randomization, n (%) | NS | |||
| CR or VGPR | 94 (47) | 92 (47) | 100 (50) | |
| PR | 84 (42) | 84 (43) | 78 (39) | |
| MR | 20 (10) | 16 (8) | 20 (10) | |
| PD | 2 (1) | 4 (2) | 3 (1) | |
| Best response after randomization, n (%) | .001 | |||
| CR or VGPR | 110 (55) | 112 (57) | 135 (67) | |
| PR | 74 (37) | 72 (37) | 60 (30) | |
| MR | 15 (7.5) | 11 (5.5) | 6 (3) | |
| PD | 1 (0.5) | 1 (0.5) | 0 |
VAD indicates vincristine, doxorubicin, and dexamethasone; CR indicates a complete response; VGPR, very good partial response; PR, partial response; MR, minimal response; PD, progressive disease; and NS, not significant.